Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4

Area of Science:

• Biomedical Engineering
• Immunology
• Oncology

Background:

• Combination immune checkpoint therapies (ICTs) show promise in cancer treatment but face limitations due to high costs and increased toxicity.
• Existing single-agent immunotherapies often have suboptimal efficacy, necessitating improved therapeutic strategies.

Purpose of the Study:

• To develop a novel smart agent, KN046@¹⁹F-ZIF-8, for enhanced cancer immunotherapy.
• To overcome the limitations of cost and side effects associated with combination ICTs.
• To improve the efficacy and safety profile of PD-L1/CTLA-4 blockade therapy.

Main Methods:

• Development of KN046, a bispecific antibody targeting PD-L1 and CTLA-4.
• Integration of KN046 into a smart delivery system, ¹⁹F-ZIF-8.
• In vitro and in vivo evaluation of the smart agent's antitumor efficacy and safety.

Main Results:

• KN046@¹⁹F-ZIF-8 demonstrated effective binding to both PD-L1 and CTLA-4.
• The smart agent successfully delivered KN046 to tumor sites.
• In vitro and in vivo studies confirmed enhanced immune response and reduced toxic side effects.
• Excellent antitumor efficacy was achieved with the novel smart agent.

Conclusions:

• KN046@¹⁹F-ZIF-8 represents a promising engineering strategy for advanced cancer immunotherapy.
• The smart agent improves upon existing combination therapies by enhancing efficacy and mitigating adverse effects.
• This approach offers a potential pathway for more effective and safer clinical applications of immunotherapy.